Long-term TAK-360 treatment for narcolepsy and idiopathic hypersomnia
Checks long-term safety of TAK-360 for narcolepsy and idiopathic hypersomnia.
Key facts
- Who runs it
- Takeda
- Where
- Atlanta, Austin, Bowie, Brandon, Chula Vista, Cincinnati, Colorado Springs, Columbia, Denver, Huntersville, Lansing, Miami, Middletown, Norfolk, San Antonio, Santa Ana, Southfield, St Louis, Winston-Salem, and Winter Park, United StatesSee the 22 sitesAlso in 4 other countries, 11 sites
- Trial code
- NCT07646678
- EU 2025-522833-68-01
- JRCT2031260198
- Registry title
- A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 500 people, planned
- Started
- 11 Jun 2026
- Expected to end
- 15 Jun 2031
- Type of study
- Interventional
- Treatments tested
- TAK-360
- Placebo
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narcolepsy type 1, narcolepsy type 2 or idiopathic hypersomnia who finished an earlier TAK-360 trial. It studies the long-term safety of TAK-360.
- Age
- 18 Years to 71 Years
- Sex
- All sexes can join.
- Disease stage
- A confirmed diagnosis of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) or idiopathic hypersomnia (IH).
- Earlier treatment
- People must have completed the treatment period of an earlier (parent) TAK-360 trial, such as TAK-360-2001 or TAK-360-2002.
Main reasons for not taking part
- Positive pregnancy test, or breastfeeding.
- Risk of suicide, based on item 4 or 5 of the C-SSRS questionnaire.
- A new medical problem causing daytime sleepiness, or new seizures.
- Stroke, mini-stroke (less than 5 years ago), brain bleeding, or serious heart disease.
- Cancer in the past 5 years, or another severe long-term illness.
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Participant is willing and able to understand and fully comply with trial procedures and requirements
- Participant has a confirmed diagnosis of either NT1, NT2, or IH, and has completed the treatment period of a parent TAK-360 trial
- Participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form (ICF) and any required privacy authorization before the initiation of any trial procedures
Who cannot take part
- The participant has developed a new medical disorder associated with excessive daytime sleep (EDS)
- Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs
- Participant has developed a new history of seizures
- Participant has developed a history of cerebral ischemia, transient ischemic attack (less than [<] 5 years ago), or cerebral haemorrhage
- Participant has developed a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure
- The participant has been diagnosed with medically significant thyroid disease, known functional hepatic impairment, or other severe chronic medical condition other than the central hypersomnolence disorder
- Participant has developed a history of cancer in the past 5 years
- Participant has a positive pregnancy test or is lactating/breastfeeding
- Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Participant has experienced clinically significant head injury, per investigator opinion
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 71 years old?
Where in United States
Also in 4 other countries, 11 sites
- Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
- Austin, TexasHospital not named in the registryContact: Study DirectorTaking people
- Bowie, MarylandHospital not named in the registryContact: Study DirectorTaking people
- Brandon, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Chula Vista, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
- Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
- Colorado Springs, ColoradoHospital not named in the registryContact: Study DirectorTaking people
- Columbia, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Denver, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Huntersville, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Lansing, MichiganHospital not named in the registryContact: Study DirectorTaking people
- Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Middletown, New JerseyHospital not named in the registryContact: Study DirectorTaking people
- Norfolk, VirginiaHospital not named in the registryContact: Study DirectorTaking people
- San Antonio, TexasHospital not named in the registryContact: Study DirectorTaking people
- Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Southfield, MichiganHospital not named in the registryContact: Study DirectorTaking people
- St Louis, MissouriHospital not named in the registryContact: Study DirectorTaking people
- Winston-Salem, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Winter Park, FloridaHospital not named in the registryContact: Study DirectorTaking people
About the trial
What the trial wants to find out
Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS). These conditions usually include narcolepsy (type 1 and 2) and idiopathic hypersomnia (IH). Narcolepsy type 1 (NT1) includes sudden muscle weakness while you stay awake, called cataplexy, often triggered by strong emotions. Narcolepsy type 2 (NT2) does not include cataplexy. People with narcolepsy typically feel refreshed by short naps. People with IH feel extremely sleepy during the day, and do not feel refreshed by sleep. Waking up from sleep is difficult. This is common in the morning and also when waking up from long naps.
Read full original descriptionShow less
The study wants to learn about TAK-360 when taken over a long time period; this is called a long-term extension or LTE study. The main aim of this LTE study is to find out how well participants with NT1, NT2, and IH tolerate TAK-360 over a longer period (long-term tolerability) and to learn how safe TAK-360 is when given over a longer period of time (long-term safety).
Participants who completed one of the TAK-360 parent studies can join this study if they meet the study rules. Parent studies include TAK-360-2001(NCT06952699), TAK-360-2002 (NCT06812078), or other TAK-360 studies that evaluate the TAK-360 medicine. All participants will receive TAK-360 in this study. They will either receive the same dose as they did in the parent study, or the closest dose available in this LTE study. Participants who received placebo (the placebo looks just like TAK-360 but does not have any medicine in it) in their parent study will receive one of the TAK-360 doses available in this study. Placebo will only be used to not reveal the dose of TAK-360 from parent studies to investigator, participants, and sponsor. Sponsor, investigators and participants will not know which TAK-360 dose was used in the LTE study as long as the parent study is ongoing.
The participants will have to visit the clinic multiple times during this study.
The group in the trial
- TAK-360 Long Term Extension (LTE) PhaseTreatment being tested
Participants will receive one of the available TAK-360 doses for up to approximately 5 years in this trial. Participants will enter the LTE on the dose they were in the parent trial or for participants with discontinued dosing regimen in the parent trial to the next closest available dose/dosing regimen for their indication in this trial. Participants rolling over to this trial from a placebo arm in the parent trial, will receive one of the available TAK-360 doses. Placebo will be only administered as needed to maintain dose blinding between TAK-360 doses and regimens.
Treatment: TAK-360 and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-360 in Participants With Selected Central Hypersomnia Conditions
- Plain-language title
- Long-term TAK-360 treatment for narcolepsy and idiopathic hypersomniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07646678, who can take part
- Record updated
- 5 November 2026